about
Vitamin B and its derivatives for diabetic kidney diseaseHorizon 2020 in Diabetic Kidney Disease: The Clinical Trial Pipeline for Add-On Therapies on Top of Renin Angiotensin System BlockadeRenal Biopsy in Type 2 Diabetic PatientsPresent and future in the treatment of diabetic kidney diseaseSite-specific AGE modifications in the extracellular matrix: a role for glyoxal in protein damage in diabetesDiabetic kidney disease: from physiology to therapeuticsDiabetic Kidney Disease: Pathophysiology and Therapeutic TargetsEfficacy and safety of tangshen formula on patients with type 2 diabetic kidney disease: a multicenter double-blinded randomized placebo-controlled trialDiabetic nephropathy induces alterations in the glomerular and tubule lipid profiles.Diabetic nephropathy - complications and treatment.Emerging drugs for chronic kidney disease.Effect of pentoxifylline on renal function and urinary albumin excretion in patients with diabetic kidney disease: the PREDIAN trial.Skin autofluorescence as a novel marker of vascular damage in children and adolescents with chronic kidney diseaseNovel Therapies for Diabetic Kidney Disease: Storied Past and Forward Paths.Effects of sevelamer on HbA1c, inflammation, and advanced glycation end products in diabetic kidney diseasePyridoxamine protects proteins from damage by hypohalous acids in vitro and in vivo.Skin autofluorescence as a marker of cardiovascular risk in children with chronic kidney disease.Diabetic nephropathy: What does the future hold?Implications of treatment that target protective mechanisms against diabetic nephropathy5'-O-Alkylpyridoxamines: Lipophilic Analogues of Pyridoxamine Are Potent Scavengers of 1,2-Dicarbonyls.Novel drugs and intervention strategies for the treatment of chronic kidney disease.Pretreatment with pyridoxamine mitigates isolevuglandin-associated retinal effects in mice exposed to bright light.Current therapeutic interventions in the glycation pathway: evidence from clinical studies.Glomerular disease in 2012: more mechanistic insights, but translational progress is slow.Emerging drugs for managing kidney disease in patients with diabetes.Advanced glycation end-products: a common pathway in diabetes and age-related erectile dysfunction.Have we reached the limits for the treatment of diabetic nephropathy?Therapeutic approaches to diabetic nephropathy--beyond the RAS.Natural product and natural product derived drugs in clinical trials.Novel effective drugs for diabetic kidney disease? or not?The role of methylglyoxal and the glyoxalase system in diabetes and other age-related diseases.Species differences in regulation of renal proximal tubule transport by certain moleculesNew and old agents in the management of diabetic nephropathy.The next generation of therapeutics for chronic kidney diseaseDiabetic kidney disease: a role for advanced glycation end-product receptor 1 (AGE-R1)?The Gomez' equations and renal hemodynamic function in kidney disease research.Novel avenues for treating diabetic nephropathy: new investigational drugs.Dicarbonyls and Advanced Glycation End-Products in the Development of Diabetic Complications and Targets for Intervention.Pyridoxamine reduces postinjury fibrosis and improves functional recovery after acute kidney injuryInvolvement of advanced glycation end-products in 'hyperglycemic memory'.
P2860
Q24186641-EC3EE723-5C7A-4694-A02F-31B615BA7201Q26799443-369E835F-6482-411E-992B-C34F67C5C3DBQ26799509-25B67284-5A0D-4F4F-9752-493B67157002Q26864133-1E5F2005-2A62-4DA0-8BE9-FFC5A9C688A3Q26865565-0E9203CB-4E66-4BBC-8E99-3F132694476BQ27021392-70564A6E-0E34-4C96-9BC5-03F4DD0AFE50Q28086840-6B769926-9EE3-4FF6-9C58-E02DF235C36AQ28546969-68A9C992-422B-40FD-9DE4-24FDBF9CD100Q30407920-BC4CC455-4F48-4E0B-AC60-0C3B878F2E1AQ34387952-45C1E06E-E65E-47FF-9821-F1C30ED24191Q34420383-5D04C49F-91C1-4FC2-8C10-7213CF767E65Q34787799-5E705596-2F7B-4174-9BE8-0C3688ADFCFCQ35214629-F16C5A9D-C611-4B99-9504-63D30A1FA29FQ35953867-BDA392FC-5A8A-460B-B12F-84A097763521Q35995060-535A8234-3790-4FE0-A166-7DCD8CD3709EQ36386384-C409CA63-8D87-438C-BB3A-FA76175E1D87Q36420791-65569ED7-3584-42A4-8BB4-5CC25C06C38EQ36441616-E9CF4F19-2478-4100-B44E-DE739004A579Q36645971-D7E4F95B-7CE7-4D36-982B-D9FC2BF78951Q37200477-91BB394A-7386-4906-83A6-FC24F35B08B6Q37219043-8AD6D59A-944C-48AC-BDF6-388E8A71C27BQ37226073-2A4370C4-DD8F-4DD4-B376-E6315F030CD9Q38070906-52493448-E4E1-474F-89F2-EC7F1195425DQ38072298-F145E06F-8233-44E1-ADA5-81E75BC7E3BBQ38075029-AFB4068F-98F0-45C5-8E55-DA8155B3B739Q38118993-1FA586B3-368A-4ED6-910A-3C851CEE25AFQ38189884-0A7C32B4-D81E-43D5-ADC0-8E1D55394AEFQ38209811-D84B80C9-079D-4872-922B-8846EB51F761Q38247457-AD2E981F-1433-47E1-B242-AAF7F159E6FFQ38265818-076B9F1B-1F2A-40E1-8039-16E51C11C302Q38394355-556D4CDC-B362-4E56-A1A1-E2607F570993Q38463854-0CA42FC8-53C1-4E3B-8FED-FF6419CBB7E1Q38738871-10FD578C-0DB9-44A3-9FF7-28B0BBBE3307Q38845590-1C31D70E-15C5-42AD-80CF-1600EF17C3CDQ38857652-3FAC77F7-51C5-4118-A943-FBDE3857DBB6Q38949048-4791154D-FE76-4A53-802D-DD491152C2B4Q39170387-FFCC84B6-7F02-4C7D-8292-12AD0E945A4FQ39285661-7B41445D-7652-4A20-8B7D-E23F54C5F2E0Q39754544-243D2E58-3353-4C34-BBA1-EFAC5CAE5FF5Q40716419-3A7CA1D1-95A7-4B90-AAEF-891207F628AF
P2860
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
Pyridorin in type 2 diabetic nephropathy.
@ast
Pyridorin in type 2 diabetic nephropathy.
@en
type
label
Pyridorin in type 2 diabetic nephropathy.
@ast
Pyridorin in type 2 diabetic nephropathy.
@en
prefLabel
Pyridorin in type 2 diabetic nephropathy.
@ast
Pyridorin in type 2 diabetic nephropathy.
@en
P2093
P2860
P356
P1476
Pyridorin in type 2 diabetic nephropathy.
@en
P2093
Anne T Reutens
David K Packham
Edmund J Lewis
Itamar Raz
Julia B Lewis
Lawrence G Hunsicker
Marc A Pohl
Richard D Rohde
Robert C Atkins
Samuel Blumenthal
P2860
P304
P356
10.1681/ASN.2011030272
P577
2011-10-27T00:00:00Z